Yuan L, Kang S Y, Ward L A, To T L, Saif L J
Department of Veterinary Preventive Medicine, Ohio Agriculture Research and Development Center, The Ohio State University, Wooster 44691-4096, USA.
J Virol. 1998 Jan;72(1):330-8. doi: 10.1128/JVI.72.1.330-338.1998.
Newborn gnotobiotic pigs were inoculated twice perorally (p.o.) (group 1) or intramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inactivated Wa strain human rotavirus and challenged with virulent Wa human rotavirus 20 to 24 days later. To assess correlates of protection, antibody-secreting cells (ASC) were enumerated in intestinal and systemic lymphoid tissues from pigs in each group at selected postinoculation days (PID) or postchallenge days. Few virus-specific ASC were detected in any tissues of group 1 pigs prior to challenge. By comparison, groups 2 and 3 had significantly greater numbers of virus-specific immunoglobulin M (IgM) ASC in intestinal and splenic tissues at PID 8 and significantly greater numbers of virus-specific IgG ASC and IgG memory B cells in spleen and blood at challenge. However, as for group 1, few virus-specific IgA ASC or IgA memory B cells were detected in any tissues of group 2 and 3 pigs. Neither p.o. nor i.m. inoculation conferred significant protection against virulent Wa rotavirus challenge (0 to 6% protection rate), and all groups showed significant anamnestic virus-specific IgG and IgA ASC responses. Hence, high numbers of IgG ASC or memory IgG ASC in the systemic lymphoid tissues at the time of challenge did not correlate with protection. Further, our findings suggest that inactivated Wa human rotavirus administered either p.o. or parenterally is significantly less effective in inducing intestinal IgA ASC responses and conferring protective immunity than live Wa human rotavirus inoculated orally, as reported earlier (L. Yuan, L. A. Ward, B. I. Rosen, T. L. To, and L. J. Saif, J. Virol. 70:3075-3083, 1996). Thus, more efficient mucosal delivery systems and rotavirus vaccination strategies are needed to induce intestinal IgA ASC responses, identified previously as a correlate of protective immunity to rotavirus.
新生无菌猪通过口服(第1组)或肌肉注射(第2组)方式接种两次灭活的沃克株人轮状病毒,或通过肌肉注射方式接种三次(第3组),并在20至24天后用强毒株沃克人轮状病毒进行攻毒。为评估保护相关性,在选定的接种后天数(PID)或攻毒后天数,对每组猪的肠道和全身淋巴组织中的抗体分泌细胞(ASC)进行计数。在攻毒前,第1组猪的任何组织中均未检测到少量病毒特异性ASC。相比之下,第2组和第3组在PID 8时肠道和脾脏组织中的病毒特异性免疫球蛋白M(IgM)ASC数量显著更多,在攻毒时脾脏和血液中的病毒特异性IgG ASC和IgG记忆B细胞数量显著更多。然而,与第1组一样,在第2组和第3组猪的任何组织中均未检测到少量病毒特异性IgA ASC或IgA记忆B细胞。口服或肌肉注射接种均未对强毒株沃克轮状病毒攻毒提供显著保护(保护率为0至6%),所有组均显示出显著的病毒特异性IgG和IgA ASC回忆反应。因此,攻毒时全身淋巴组织中大量的IgG ASC或记忆性IgG ASC与保护无关。此外,我们的研究结果表明,如先前报道(L. Yuan、L. A. Ward、B. I. Rosen、T. L. To和L. J. Saif,J. Virol. 70:3075 - 3083,1996),口服或胃肠外给予灭活的沃克人轮状病毒在诱导肠道IgA ASC反应和赋予保护性免疫方面明显不如口服接种活的沃克人轮状病毒有效。因此,需要更有效的黏膜递送系统和轮状病毒疫苗接种策略来诱导肠道IgA ASC反应,此前已确定该反应是对轮状病毒保护性免疫的一个相关因素。